Observational study finds nearly half of hospitalized COVID-19 patients experience viral reactivation — Evidence Review
Published in Nature, by researchers from University of Virginia, University of Texas at Austin
Researched by
— the AI search engine for science
Table of Contents
A new study finds that severe COVID-19 can trigger the reactivation of dormant viruses, including Epstein-Barr virus and anelloviruses, which may be linked to long-term physical disability. Existing research largely supports these findings, showing that viral reactivation and persistent symptoms are common after severe COVID-19 (1, 2, 5).
- Multiple studies have documented reactivation of herpesviruses, such as Epstein-Barr virus (EBV) and cytomegalovirus (CMV), in patients with severe COVID-19, supporting the observation that latent viruses can awaken during acute infection and may contribute to complications (1, 2, 4, 5).
- Long COVID symptoms, including fatigue and reduced physical capacity, are frequently reported and may be associated with viral reactivation; several studies link EBV reactivation specifically to persistent post-COVID symptoms (1, 5, 6, 9, 11).
- The new study adds novel evidence by highlighting a potential association between anellovirus reactivation and long COVID, suggesting future research should expand beyond well-known herpesviruses (3, 4).
Study Overview and Key Findings
Understanding the long-term effects of COVID-19 remains a critical area of investigation, as millions worldwide continue to experience persistent symptoms following infection. While prior research has established links between severe COVID-19 and lasting complications, the mechanism by which the virus may trigger new or worsening health issues is still being explored. This study is significant as it provides one of the largest and most detailed investigations into how severe COVID-19 may lead to the reactivation of dormant viruses and associates this reactivation with long-term physical disability, even in individuals with previously healthy immune systems.
| Property | Value |
|---|---|
| Study Year | 2023 |
| Organization | University of Virginia, University of Texas at Austin |
| Journal Name | Nature |
| Authors | Esther Melamed |
| Population | Adults hospitalized with COVID-19 |
| Sample Size | n=1,154 |
| Methods | Observational Study |
| Outcome | Viral reactivation, long COVID symptoms |
| Results | Nearly half of patients had at least one virus reactivate. |
Literature Review: Related Studies
To provide context for this study, we searched the Consensus paper database, which includes over 200 million research papers. The following search queries were used to identify relevant studies:
- COVID-19 dormant virus reactivation
- long-term effects of COVID-19
- physical disability after severe COVID-19
| Topic | Key Findings |
|---|---|
| How common is viral reactivation during and after COVID-19, and which viruses are involved? | - Human herpesvirus (e.g., EBV, CMV, HSV) reactivation is common in severe COVID-19, with incidence rates of up to 45% for EBV and 38% for HSV (1, 2, 4, 5). - EBV reactivation occurs frequently during COVID-19 and is associated with worse clinical outcomes and complications (1, 2, 5). |
| What are the long-term physical and mental health effects of COVID-19 (long COVID)? | - Between 45% and 80% of COVID-19 survivors experience at least one unresolved symptom up to 12 months post-infection; fatigue, reduced physical capacity, and mental health issues are most common (6, 7, 8, 9, 11, 12). - Severe cases are more likely to result in persistent symptoms and disability (7, 14). |
| Is there evidence linking viral reactivation (esp. EBV, CMV) to long COVID symptoms and disability? | - EBV reactivation is significantly more common in those with long COVID compared to those without, suggesting a potential causal relationship (1, 5). - Reactivated herpesviruses may contribute to post-COVID syndrome and increase the risk of developing various pathologies, including rheumatic and neurological symptoms (5, 14). |
| What mechanisms could explain viral reactivation and lasting symptoms after COVID-19? | - Immune dysregulation and inflammation during acute COVID-19 can "let down the guard" against dormant viruses, leading to their reactivation (1, 3, 5). - Persistent SARS-CoV-2 RNA or antigens and heightened inflammatory responses may drive ongoing symptoms and facilitate viral reactivation (3, 4). |
How common is viral reactivation during and after COVID-19, and which viruses are involved?
Several studies have found that viral reactivation, particularly of herpesviruses such as EBV, CMV, and HSV, is a frequent occurrence in patients with severe COVID-19. The new study's finding that nearly half of hospitalized adults had at least one virus reactivate aligns with existing evidence, reinforcing the idea that severe infection creates conditions conducive to viral reawakening.
- Meta-analyses report cumulative incidence rates of 38% for HSV, 45% for EBV, and 19% for CMV reactivation in severe COVID-19 cases (2).
- Cross-sectional and observational studies have independently confirmed high rates of EBV and CMV reactivation during acute COVID-19 (1, 4, 5).
- The new study extends these findings by including anelloviruses, which are not typically linked to disease but may play a role in post-COVID complications (3, 4).
What are the long-term physical and mental health effects of COVID-19 (long COVID)?
Long COVID, characterized by ongoing symptoms such as fatigue, muscle weakness, and cognitive issues, is well-documented in the literature. The present study's association between viral reactivation and long-term disability complements prior findings that persistent symptoms are common, especially after severe illness.
- Systematic reviews and meta-analyses estimate that 45–80% of COVID-19 survivors experience at least one long-term symptom, with fatigue, reduced exercise capacity, and neuropsychiatric symptoms most prevalent (6, 7, 8, 9, 11, 12).
- Hospitalized and severe cases show higher rates of ongoing physical disability and impaired daily functioning (7, 14).
- Long COVID can include a wide spectrum of symptoms, not limited to respiratory or cardiovascular issues (8, 9, 11).
Is there evidence linking viral reactivation (esp. EBV, CMV) to long COVID symptoms and disability?
Emerging research increasingly supports a connection between viral reactivation—especially of EBV—and persistent post-COVID symptoms. The current study's observation that anellovirus reactivation correlates with lasting disability is a novel contribution, but the link between herpesvirus reactivation and long COVID is well-substantiated.
- EBV reactivation is significantly more common in patients with long COVID, with one study finding a 66.7% reactivation rate in those with persistent symptoms versus 10% in controls (1).
- Reactivated herpesviruses are associated with more severe and diverse post-COVID manifestations, including rheumatologic and neurological issues (5, 14).
- The literature suggests the relationship is associative rather than definitively causal, consistent with the new study's conclusions (1, 4, 5).
What mechanisms could explain viral reactivation and lasting symptoms after COVID-19?
Investigations into the underlying mechanisms suggest that immune dysregulation and inflammation during acute COVID-19 are key drivers. The immune system's "distraction" by SARS-CoV-2 may allow dormant viruses to reactivate, with ongoing inflammation potentially sustaining symptoms.
- Stressors such as severe infection, inflammation, and immune modulation are known triggers for herpesvirus reactivation, even in otherwise healthy individuals (1, 3, 5).
- Persistent viral RNA or antigens from SARS-CoV-2 and ongoing immune activation may perpetuate both viral reactivation and long-term symptoms (3, 4).
- The mechanisms remain incompletely understood, underscoring the need for interventional research and mechanistic studies (3, 4, 5).
Future Research Questions
Given the observational nature of current studies and the complex interplay between viral reactivation, immune response, and long-term symptoms, further research is warranted to clarify causality and inform clinical management.
| Research Question | Relevance |
|---|---|
| Can antiviral therapy for reactivated viruses improve long COVID outcomes? | Interventional trials are needed to determine if treating viral reactivation (e.g., EBV, anelloviruses) can reduce the burden of long COVID symptoms, as existing studies show strong associations but not causation (1, 3, 5). |
| What is the role of anelloviruses in human disease and long COVID? | The new study implicates anelloviruses in persistent disability, but their pathogenic potential remains unclear and unexplored in prior research (3, 4). |
| Are certain individuals more susceptible to viral reactivation after COVID-19? | Identifying risk factors (e.g., genetics, comorbidities, immune profiles) for viral reactivation may enable targeted prevention and management of long COVID (7, 11, 14). |
| What immune mechanisms drive viral reactivation during COVID-19? | A better understanding of how SARS-CoV-2 infection modulates immune surveillance and permits viral reactivation could inform both treatment and prevention strategies (1, 3, 5). |
| How do long-term outcomes differ between patients with and without viral reactivation after COVID-19? | Stratifying long COVID patients by viral reactivation status could clarify the contribution of latent viruses to persistent disability and guide future research and clinical care (1, 5, 14). |
This article is for informational purposes and does not constitute medical advice.